Irazu Oncology
Baltimore, US · Founded 2022 · Delaware LLC · 2 known investors
Irazú Oncology develops cancer immunotherapies using a proprietary Outer Membrane Vesicles (OMV) platform based on engineered bacterial nanoparticles that deliver cancer antigens. The biotech company, founded in 2022, is building a pipeline of immunotherapies for cancer patients.
Founders & leadership
JS
Jeff StrovelChief Executive Officer
JB
James BerensNamed on SEC filing
RK
Richard KohrNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$2.6M disclosed across 1 round · 2023
▶$2.6MraisedDec 2023 · 6 investors · BiotechnologyRule 506(b)
▶$2.6MraisedDec 2023 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James BerensExecutive Officer
- Richard KohrExecutive Officer
- Offering amount
- $3.9M
- Amount sold
- $2.6M
- First sale
- Nov 2023
- Incorporated
- Limited Liability Company, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Irazu Oncology do?
- Irazú Oncology develops cancer immunotherapies using a proprietary Outer Membrane Vesicles (OMV) platform based on engineered bacterial nanoparticles that deliver cancer antigens. The biotech company, founded in 2022, is building a pipeline of immunotherapies for cancer patients.
- Who are Irazu Oncology's investors?
- Irazu Oncology's investors include Maryland TEDCO, TEDCO.
- How much funding has Irazu Oncology raised?
- Irazu Oncology has disclosed $2.6M raised across 1 round.
- Where is Irazu Oncology headquartered?
- Irazu Oncology is headquartered in Baltimore, US.